Evommune, Inc. (NYSE: EVMN) Stock Competitors & Peer Comparison
See EVMN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EVMN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EVMN | $11.47 | +0.97% | 162.6M | -1.13 | -$10.14 | N/A |
| VRTX | $479.00 | +0.34% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.17 | +1.70% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $888.82 | -3.20% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.07 | -0.61% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $9.55 | +0.53% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $278.40 | +2.44% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $325.90 | +0.00% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
EVMN vs VRTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while VRTX trades at $479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas VRTX's P/E ratio is 25.45. In terms of profitability, EVMN's ROE is -1.95%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, EVMN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
EVMN vs VRNA Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas VRNA's P/E ratio is -102.80. In terms of profitability, EVMN's ROE is -1.95%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, EVMN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
EVMN vs REGN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while REGN trades at $667.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas REGN's P/E ratio is 14.62. In terms of profitability, EVMN's ROE is -1.95%, compared to REGN's ROE of +0.14%. Regarding short-term risk, EVMN is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
EVMN vs ARGX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ARGX trades at $888.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ARGX's P/E ratio is 80.22. In terms of profitability, EVMN's ROE is -1.95%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, EVMN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
EVMN vs SGEN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EVMN's ROE is -1.95%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EVMN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
EVMN vs RVMD Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RVMD trades at $188.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RVMD's P/E ratio is -26.60. In terms of profitability, EVMN's ROE is -1.95%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, EVMN is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
EVMN vs RVMDW Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, EVMN's ROE is -1.95%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, EVMN is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
EVMN vs ALNY Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ALNY trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ALNY's P/E ratio is 50.16. In terms of profitability, EVMN's ROE is -1.95%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, EVMN is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
EVMN vs ONC Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ONC's P/E ratio is 72.91. In terms of profitability, EVMN's ROE is -1.95%, compared to ONC's ROE of +0.12%. Regarding short-term risk, EVMN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
EVMN vs ROIV Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ROIV trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ROIV's P/E ratio is -35.69. In terms of profitability, EVMN's ROE is -1.95%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, EVMN is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
EVMN vs INCY Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while INCY trades at $118.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas INCY's P/E ratio is 15.98. In terms of profitability, EVMN's ROE is -1.95%, compared to INCY's ROE of +0.29%. Regarding short-term risk, EVMN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
EVMN vs BNTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while BNTX trades at $91.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas BNTX's P/E ratio is -19.72. In terms of profitability, EVMN's ROE is -1.95%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, EVMN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
EVMN vs INSM Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while INSM trades at $104.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas INSM's P/E ratio is -18.21. In terms of profitability, EVMN's ROE is -1.95%, compared to INSM's ROE of -1.30%. Regarding short-term risk, EVMN is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
EVMN vs UTHR Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while UTHR trades at $527.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas UTHR's P/E ratio is 19.49. In terms of profitability, EVMN's ROE is -1.95%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EVMN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
EVMN vs MRNA Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MRNA trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MRNA's P/E ratio is -6.83. In terms of profitability, EVMN's ROE is -1.95%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, EVMN is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
EVMN vs BGNE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EVMN's ROE is -1.95%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, EVMN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
EVMN vs DNA-WT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EVMN's ROE is -1.95%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, EVMN is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
EVMN vs NBIX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while NBIX trades at $176.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas NBIX's P/E ratio is 25.49. In terms of profitability, EVMN's ROE is -1.95%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, EVMN is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
EVMN vs GMAB Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas GMAB's P/E ratio is 20.72. In terms of profitability, EVMN's ROE is -1.95%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, EVMN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
EVMN vs BBIO Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while BBIO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas BBIO's P/E ratio is -22.49. In terms of profitability, EVMN's ROE is -1.95%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, EVMN is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
EVMN vs JAZZ Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while JAZZ trades at $255.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, EVMN's ROE is -1.95%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, EVMN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
EVMN vs ASND Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ASND trades at $253.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ASND's P/E ratio is -104.72. In terms of profitability, EVMN's ROE is -1.95%, compared to ASND's ROE of -56.42%. Regarding short-term risk, EVMN is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
EVMN vs EXEL Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while EXEL trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas EXEL's P/E ratio is 16.71. In terms of profitability, EVMN's ROE is -1.95%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, EVMN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
EVMN vs MDGL Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MDGL trades at $551.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MDGL's P/E ratio is -43.07. In terms of profitability, EVMN's ROE is -1.95%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, EVMN is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
EVMN vs KRTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EVMN's ROE is -1.95%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EVMN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
EVMN vs AXSM Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while AXSM trades at $238.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas AXSM's P/E ratio is -62.24. In terms of profitability, EVMN's ROE is -1.95%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, EVMN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
EVMN vs ARWR Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ARWR trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ARWR's P/E ratio is -39.78. In terms of profitability, EVMN's ROE is -1.95%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, EVMN is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
EVMN vs BMRN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while BMRN trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas BMRN's P/E ratio is 28.98. In terms of profitability, EVMN's ROE is -1.95%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, EVMN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
EVMN vs RNAM Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RNAM's P/E ratio is -17.39. In terms of profitability, EVMN's ROE is -1.95%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, EVMN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
EVMN vs TECH Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while TECH trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas TECH's P/E ratio is 36.91. In terms of profitability, EVMN's ROE is -1.95%, compared to TECH's ROE of +0.05%. Regarding short-term risk, EVMN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
EVMN vs KRYS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while KRYS trades at $351.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas KRYS's P/E ratio is 47.03. In terms of profitability, EVMN's ROE is -1.95%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, EVMN is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
EVMN vs SMMT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while SMMT trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas SMMT's P/E ratio is -8.19. In terms of profitability, EVMN's ROE is -1.95%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, EVMN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for EVMN.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
EVMN vs CYTK Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CYTK trades at $80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CYTK's P/E ratio is -13.83. In terms of profitability, EVMN's ROE is -1.95%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, EVMN is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
EVMN vs HALO Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while HALO trades at $81.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas HALO's P/E ratio is 17.64. In terms of profitability, EVMN's ROE is -1.95%, compared to HALO's ROE of +1.26%. Regarding short-term risk, EVMN is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
EVMN vs RXDX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EVMN's ROE is -1.95%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EVMN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
EVMN vs ABVX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ABVX trades at $128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ABVX's P/E ratio is -67.09. In terms of profitability, EVMN's ROE is -1.95%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, EVMN is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
EVMN vs IONS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while IONS trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas IONS's P/E ratio is -32.53. In terms of profitability, EVMN's ROE is -1.95%, compared to IONS's ROE of -0.59%. Regarding short-term risk, EVMN is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
EVMN vs NUVL Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas NUVL's P/E ratio is -21.79. In terms of profitability, EVMN's ROE is -1.95%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, EVMN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
EVMN vs KYMR Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while KYMR trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas KYMR's P/E ratio is -31.18. In terms of profitability, EVMN's ROE is -1.95%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, EVMN is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
EVMN vs CRNX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CRNX trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CRNX's P/E ratio is -16.35. In terms of profitability, EVMN's ROE is -1.95%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, EVMN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
EVMN vs PRAX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while PRAX trades at $315.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas PRAX's P/E ratio is -23.62. In terms of profitability, EVMN's ROE is -1.95%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, EVMN is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
EVMN vs ALKS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ALKS trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ALKS's P/E ratio is 55.51. In terms of profitability, EVMN's ROE is -1.95%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, EVMN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
EVMN vs IMGN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EVMN's ROE is -1.95%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, EVMN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
EVMN vs PTGX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while PTGX trades at $135.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas PTGX's P/E ratio is -74.90. In terms of profitability, EVMN's ROE is -1.95%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, EVMN is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
EVMN vs SYRE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while SYRE trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas SYRE's P/E ratio is -48.10. In terms of profitability, EVMN's ROE is -1.95%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, EVMN is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
EVMN vs TGTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while TGTX trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas TGTX's P/E ratio is 19.16. In terms of profitability, EVMN's ROE is -1.95%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, EVMN is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
EVMN vs BPMC Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas BPMC's P/E ratio is -51.58. In terms of profitability, EVMN's ROE is -1.95%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, EVMN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
EVMN vs APGE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas APGE's P/E ratio is -31.01. In terms of profitability, EVMN's ROE is -1.95%, compared to APGE's ROE of -0.33%. Regarding short-term risk, EVMN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
EVMN vs IMVT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while IMVT trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas IMVT's P/E ratio is -15.01. In terms of profitability, EVMN's ROE is -1.95%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, EVMN is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
EVMN vs CERE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CERE's P/E ratio is -16.47. In terms of profitability, EVMN's ROE is -1.95%, compared to CERE's ROE of -0.72%. Regarding short-term risk, EVMN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
EVMN vs PCVX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while PCVX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas PCVX's P/E ratio is -8.07. In terms of profitability, EVMN's ROE is -1.95%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, EVMN is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
EVMN vs MTSR Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MTSR's P/E ratio is -23.58. In terms of profitability, EVMN's ROE is -1.95%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, EVMN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
EVMN vs IBRX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas IBRX's P/E ratio is -8.22. In terms of profitability, EVMN's ROE is -1.95%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, EVMN is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
EVMN vs RYTM Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RYTM trades at $106.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RYTM's P/E ratio is -33.91. In terms of profitability, EVMN's ROE is -1.95%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, EVMN is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
EVMN vs MIRM Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MIRM trades at $114.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MIRM's P/E ratio is -8.39. In terms of profitability, EVMN's ROE is -1.95%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, EVMN is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
EVMN vs COGT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while COGT trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas COGT's P/E ratio is -19.17. In terms of profitability, EVMN's ROE is -1.95%, compared to COGT's ROE of -0.83%. Regarding short-term risk, EVMN is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
EVMN vs MRUS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MRUS's P/E ratio is -17.05. In terms of profitability, EVMN's ROE is -1.95%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, EVMN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
EVMN vs ACLX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ACLX's P/E ratio is -28.27. In terms of profitability, EVMN's ROE is -1.95%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, EVMN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
EVMN vs RETA Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RETA's P/E ratio is -66.29. In terms of profitability, EVMN's ROE is -1.95%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EVMN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
EVMN vs ERAS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ERAS trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ERAS's P/E ratio is -20.29. In terms of profitability, EVMN's ROE is -1.95%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, EVMN is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
EVMN vs CGON Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CGON trades at $73.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CGON's P/E ratio is -31.55. In terms of profitability, EVMN's ROE is -1.95%, compared to CGON's ROE of -0.23%. Regarding short-term risk, EVMN is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
EVMN vs XENE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while XENE trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas XENE's P/E ratio is -14.00. In terms of profitability, EVMN's ROE is -1.95%, compared to XENE's ROE of -0.49%. Regarding short-term risk, EVMN is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
EVMN vs BLTE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while BLTE trades at $158.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas BLTE's P/E ratio is -84.72. In terms of profitability, EVMN's ROE is -1.95%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, EVMN is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
EVMN vs PTCT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while PTCT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas PTCT's P/E ratio is -32.53. In terms of profitability, EVMN's ROE is -1.95%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, EVMN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
EVMN vs CNTA Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CNTA's P/E ratio is -22.63. In terms of profitability, EVMN's ROE is -1.95%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, EVMN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
EVMN vs LGND Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while LGND trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas LGND's P/E ratio is 35.67. In terms of profitability, EVMN's ROE is -1.95%, compared to LGND's ROE of +0.16%. Regarding short-term risk, EVMN is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
EVMN vs SRRK Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while SRRK trades at $48.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas SRRK's P/E ratio is -13.63. In terms of profitability, EVMN's ROE is -1.95%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, EVMN is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
EVMN vs CDTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CDTX's P/E ratio is -19.77. In terms of profitability, EVMN's ROE is -1.95%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, EVMN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
EVMN vs ABCM Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EVMN's ROE is -1.95%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EVMN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
EVMN vs ISEE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EVMN's ROE is -1.95%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EVMN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
EVMN vs TVTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while TVTX trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas TVTX's P/E ratio is -257.64. In terms of profitability, EVMN's ROE is -1.95%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, EVMN is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
EVMN vs APLS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas APLS's P/E ratio is 38.35. In terms of profitability, EVMN's ROE is -1.95%, compared to APLS's ROE of +0.40%. Regarding short-term risk, EVMN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
EVMN vs TERN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas TERN's P/E ratio is -51.41. In terms of profitability, EVMN's ROE is -1.95%, compared to TERN's ROE of -0.20%. Regarding short-term risk, EVMN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
EVMN vs DFTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while DFTX trades at $42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas DFTX's P/E ratio is N/A. In terms of profitability, EVMN's ROE is -1.95%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, EVMN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for EVMN.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
EVMN vs MANE Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MANE trades at $111.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MANE's P/E ratio is -35.45. In terms of profitability, EVMN's ROE is -1.95%, compared to MANE's ROE of -0.84%. Regarding short-term risk, EVMN is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
EVMN vs FOLD Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas FOLD's P/E ratio is -161.00. In terms of profitability, EVMN's ROE is -1.95%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, EVMN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
EVMN vs CRSP Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CRSP trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CRSP's P/E ratio is -9.15. In terms of profitability, EVMN's ROE is -1.95%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, EVMN is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
EVMN vs AKRO Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas AKRO's P/E ratio is -14.57. In terms of profitability, EVMN's ROE is -1.95%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, EVMN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
EVMN vs EWTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while EWTX trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas EWTX's P/E ratio is -25.06. In terms of profitability, EVMN's ROE is -1.95%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, EVMN is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
EVMN vs ALPN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EVMN's ROE is -1.95%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, EVMN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
EVMN vs CAI Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CAI trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CAI's P/E ratio is -85.97. In terms of profitability, EVMN's ROE is -1.95%, compared to CAI's ROE of +0.06%. Regarding short-term risk, EVMN is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
EVMN vs DNTH Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while DNTH trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas DNTH's P/E ratio is -25.30. In terms of profitability, EVMN's ROE is -1.95%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, EVMN is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
EVMN vs ACAD Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ACAD trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ACAD's P/E ratio is 12.45. In terms of profitability, EVMN's ROE is -1.95%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, EVMN is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
EVMN vs DYN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while DYN trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas DYN's P/E ratio is -7.96. In terms of profitability, EVMN's ROE is -1.95%, compared to DYN's ROE of -0.58%. Regarding short-term risk, EVMN is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
EVMN vs OPT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas OPT's P/E ratio is -1.52. In terms of profitability, EVMN's ROE is -1.95%, compared to OPT's ROE of +1.18%. Regarding short-term risk, EVMN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
EVMN vs MRTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EVMN's ROE is -1.95%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EVMN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
EVMN vs VKTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas VKTX's P/E ratio is -8.42. In terms of profitability, EVMN's ROE is -1.95%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, EVMN is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
EVMN vs CELC Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CELC trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CELC's P/E ratio is -21.09. In terms of profitability, EVMN's ROE is -1.95%, compared to CELC's ROE of -2.45%. Regarding short-term risk, EVMN is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
EVMN vs CPRX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CPRX's P/E ratio is 12.30. In terms of profitability, EVMN's ROE is -1.95%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, EVMN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
EVMN vs ELVN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ELVN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ELVN's P/E ratio is -31.58. In terms of profitability, EVMN's ROE is -1.95%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, EVMN is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
EVMN vs RYZB Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EVMN's ROE is -1.95%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EVMN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
EVMN vs DNLI Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while DNLI trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas DNLI's P/E ratio is -8.18. In terms of profitability, EVMN's ROE is -1.95%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, EVMN is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
EVMN vs CBAY Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EVMN's ROE is -1.95%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EVMN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
EVMN vs NAMSW Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, EVMN's ROE is -1.95%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, EVMN is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
EVMN vs ADPT Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while ADPT trades at $22.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas ADPT's P/E ratio is -41.74. In terms of profitability, EVMN's ROE is -1.95%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, EVMN is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
EVMN vs LEGN Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while LEGN trades at $19.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas LEGN's P/E ratio is -28.34. In terms of profitability, EVMN's ROE is -1.95%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, EVMN is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for EVMN.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
EVMN vs SWTX Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas SWTX's P/E ratio is -13.78. In terms of profitability, EVMN's ROE is -1.95%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, EVMN is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
EVMN vs NAMS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while NAMS trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas NAMS's P/E ratio is -19.01. In terms of profitability, EVMN's ROE is -1.95%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, EVMN is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
EVMN vs RCUS Comparison July 2026
Evommune, Inc. (NYSE: EVMN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVMN stands at 162.6M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, EVMN is priced at $11.47 on the NYSE, while RCUS trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVMN currently has a P/E ratio of -1.13, whereas RCUS's P/E ratio is -8.56. In terms of profitability, EVMN's ROE is -1.95%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, EVMN is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for EVMN.Check RCUS's competition here